Cover Image

Sex differences in Alzheimer's disease blood biomarkers in a Caribbean population of African ancestry: The Tobago Health Study

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Caterina Rosano, Thomas K. Karikari, Ryan Cvejkus, Bruna Bellaver, Pamela C. L. Ferreira, Joseph Zmuda, Victor Wheeler, Tharick A. Pascoal, Iva Miljkovic
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alzheimer's & Dementia: Translational Research & Clinical Interventions
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Developing educational materials to aid in Alzheimer's blood biomarker disclosure
by: Raymond R. Romano, et al.
Published: (2025)

Simulation of Alzheimer's diagnostic flows with blood biomarker test options in Japan
by: Ataru Igarashi, et al.
Published: (2025)

Real‐world relationship between blood biomarker‐based PhenoAge, metformin, and Alzheimer's disease
by: Yi Shi, et al.
Published: (2026)

Sex differences and the role of estrogens in the immunological underpinnings of Alzheimer's disease
by: Brittani R. Price, et al.
Published: (2025)

Cerebrospinal fluid biomarker profiling of diverse pathophysiological domains in Alzheimer's disease
by: Bianca A. Trombetta, et al.
Published: (2024)

Mitochondrial blood‐based biomarker is related to cardiorespiratory fitness and aging in a sex‐dependent manner
by: Riley E. Kemna, et al.
Published: (2025)

The impact of estimated cardiorespiratory fitness on Alzheimer's disease biomarkers and their relationships with cognitive decline
by: Adam J Paulsen, et al.
Published: (2025)

Sex differences in blood pressure hemodynamics and white matter hyperintensity volume across racial ethnic groups—HABS‐HD
by: Cellas A. Hayes, et al.
Published: (2026)

Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
by: Ronald C. Petersen, et al.
Published: (2025)

Study of the utility and impact of a plasma p‐tau181 Alzheimer's biomarker (SUITABLE)
by: Kyra O'Brien, et al.
Published: (2026)

Relationship between physical activity and biomarkers of pathology and neuroinflammation in preclinical autosomal‐dominant Alzheimer's disease
by: Edmarie Guzmán‐Vélez, et al.
Published: (2024)

Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's disease
by: Garrett B. Duncan, et al.
Published: (2025)

Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes
by: Claire M. Erickson, et al.
Published: (2024)

Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective
by: Khushbu J. Patel, et al.
Published: (2024)

Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
by: Linda J. Van Eldik, et al.
Published: (2024)

Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
by: Pratik Bhagunde, et al.
Published: (2026)

Physical activity attenuates the association between allostatic load and early Alzheimer's disease‐related biomarkers in older adults
by: Géraldine Poisnel, et al.
Published: (2026)

Blood biomarkers for Alzheimer's disease are correlated with measures of agitation and cognition in a randomized trial assessing the effects of escitalopram on agitation
by: Maansi Barnwal, et al.
Published: (2026)

Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients
by: Dawn C. Matthews, et al.
Published: (2024)

Comparison of sample characteristics of Wisconsin Alzheimer's Disease Research Center participants with the Wisconsin state population—An evaluation of the recruitment effort
by: Yue Ma, et al.
Published: (2025)

Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment
by: Chao‐Yi Wu, et al.
Published: (2025)

Potential of low‐field MRI for increasing participation of Filipino Americans and underrepresented populations in Alzheimer's and dementia research
by: Mikkael Lamoca, et al.
Published: (2025)

Blood‐based biomarker prescreening with different testing combinations and cutoffs: A simulation study examining efficacy and cost‐effectiveness in Alzheimer's disease prevention studies
by: Kenichiro Sato, et al.
Published: (2025)

Tau biology, biomarkers, and therapeutics
by: Bess Frost, et al.
Published: (2025)

Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812
by: Valentina Di Caro, et al.
Published: (2025)

Using concept mapping to identify recruitment and engagement strategies for inclusion of LGBTQIA+ populations in Alzheimer's disease and related dementia research
by: Brittany Klenczar‐Castro, et al.
Published: (2024)

Designing and implementing the IDEAL Study: A randomized clinical trial of APOE genotype disclosure for late‐onset Alzheimer's disease in an urban Latino population
by: John B. Wetmore, et al.
Published: (2024)

The African Initiative for Bioinformatics Online Training in Neurodegenerative Diseases (AI‐BOND): Investing in the next generation of African neuroscientists
by: Bernard Fongang, et al.
Published: (2024)

Digital biomarkers: Redefining clinical outcomes and the concept of meaningful change
by: Maria Florencia Iulita, et al.
Published: (2025)

Clinically meaningful outcomes in Alzheimer's disease and Alzheimer's disease related dementias trials
by: Luke E. Stoeckel, et al.
Published: (2025)

New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop
by: Maria A. Telpoukhovskaia, et al.
Published: (2024)

Recruitment of mid‐life adults to a randomized clinical trial: The multicultural healthy diet study to reduce cognitive decline and Alzheimer's disease risk
by: Mindy J. Katz, et al.
Published: (2025)

More fit KL‐VS heterozygotes have more favorable AD‐relevant biomarker profiles
by: Mackenzie Jarchow, et al.
Published: (2025)

Association of region‐specific hippocampal reduction of neurogranin with inflammasome proteins in post mortem brains of Alzheimer's disease
by: Regina T. Vontell, et al.
Published: (2024)

Alzheimer's disease drug development pipeline: 2026
by: Jeffrey L. Cummings, et al.
Published: (2026)

Biomarkers in Alzheimer's disease clinical trials: 2025
by: Amanda M. Leisgang Osse, et al.
Published: (2026)

Alzheimer's disease drug development pipeline: 2025
by: Jeffrey L. Cummings, et al.
Published: (2025)

Combination therapy targeting Alzheimer's disease risk factors is associated with a significant delay in Alzheimer's disease–related cognitive decline
by: Yuan Shang, et al.
Published: (2025)

Plasma amyloid beta biomarkers predict amyloid positivity and longitudinal clinical progression in mild cognitive impairment
by: Takuya Ataka, et al.
Published: (2024)

Genetic associations with psychosis and affective disturbance in Alzheimer's disease
by: Inga Margret Antonsdottir, et al.
Published: (2024)